The group's principal activity is to design, manufacture, market and support eecp external counterpulsation system. The system is a microprocessor-based medical device for the non-invasive, outpatient treatment of patients with cardiovascular disease. The device is used in cases of angina, carcinogenic shock, acute myocardial infarction and most recently, congestive heart failure (chf). It delivers a retrograde arterial pressure wave to the heart, increasing coronary perfusion and reducing ventricular after load. The therapy serves to increase circulation in areas of the heart with less than adequate blood supply and restores systemic vascular function. The products of the group are sold to treatment providers in the United States through a direct sales force.
